Commodities Investing

Business

Metals Market Reels as Speculative Frenzy Cools: Chinese Investors at Center of Historic Gold, Silver Plunge

Precious metals markets experienced one of their most volatile weeks on record, with silver plummeting 26% and gold dropping 9% in a dramatic reversal. The sell-off, triggered by shifting U.S. policy expectations, laid bare the market's recent dependence on speculative flows from China, raising questions about stability ahead of the Lunar New Year.

Feb 2, 2026

Business

Goldcom's Meteoric Rise: Is the Rally Over, or Just Beginning?

Goldcom's (GOLD) shares have soared nearly 90% in the past year, leaving investors to grapple with a critical question: has the market already priced in all the good news, or is there still room to run? A deep dive into the valuation metrics reveals a stark contradiction.

Feb 2, 2026

Business

Starbucks Brews a Comeback: How AI and a Return to 'Third Place' Roots Aim to Revive the Coffee Giant

After years of sluggish sales and brand challenges, Starbucks is betting on a dual strategy: deploying AI to streamline operations while reinvesting in the in-store experience. CEO Brian Niccol outlines the plan he believes will restore growth and community connection.

Feb 2, 2026

Business

Healthcare's Bull Run: One Stock for the Long Haul, Two to Approach with Caution

The healthcare sector has surged 17.4% in six months, outpacing the S&P 500. While demographic trends fuel long-term growth, regulatory hurdles and valuation concerns demand selective investing. We analyze one company built for decades of returns and two where investors should tread carefully.

Jan 30, 2026

Business

SciDev's Turnaround Story: From Losses to Profitability as Capital Efficiency Rises

The Australian chemicals company SciDev (ASX:SDV) is showing early signs of a financial transformation, with its return on capital employed turning positive after years of losses. While its current returns still lag the industry average, a significant increase in capital deployment suggests the firm is aggressively reinvesting for growth.

Jan 30, 2026

Business

Advocate Health Announces Major Compensation Overhaul, Boosting Minimum Wage and Benefits Across Six States

Advocate Health, the nation's third-largest nonprofit health system, is investing over $800 million in enhanced compensation and benefits for its 165,000+ employees, raising its minimum wage and expanding tuition aid, mental health support, and paid volunteer time.

Jan 30, 2026

Business

Diana Shipping (DSX) in the Spotlight: How Revised Analyst Targets Are Redefining the Investment Narrative

A wave of updated price targets from Wall Street analysts is prompting investors to reassess Diana Shipping Inc. The shifting forecasts reflect changing views on dry bulk shipping fundamentals and the company's strategic position, moving the stock's story beyond recent quarters.

Jan 30, 2026

Business

Markets Tumble on Trump's Fed Pick: Warsh Nomination Sends Stocks, Metals Lower

U.S. stocks fell and precious metals plunged from record highs after President Trump nominated former Fed Governor Kevin Warsh to lead the central bank, sparking concerns over monetary policy direction and Fed independence.

Jan 30, 2026

Business

ArcBest Navigates Prolonged Freight Downturn with Cost Cuts and Tech Investments

Despite posting a Q4 net loss, ArcBest is streamlining operations and investing in technology, positioning for a market rebound while the broader LTL sector continues its slow climb from a prolonged slump.

Jan 30, 2026

World

New York Officials Face Legal Warning Over Public Investments in Israeli Bonds

A human rights group has cautioned New York state and city officials that investing public funds in Israeli government bonds may violate international law and fiduciary duties, exposing them to significant legal and financial risks.

Jan 30, 2026

Business

Gold Breaks $5,000, Silver Soars Past $100: The Unstoppable Rally Challenging Stock Market Dominance

Precious metals continue their historic surge, outpacing the S&P 500 for a third consecutive year. We examine the powerful drivers behind the rally, from industrial demand to monetary policy, and explore how investors can gain exposure through ETFs while navigating the risks.

Jan 30, 2026

Business

Beyond the Headlines: Three European Penny Stocks Drawing Investor Scrutiny Amid Market Volatility

As uncertainty shapes European markets, some investors are turning their gaze to penny stocks for potential growth. We analyze three companies—GreenMerc, Transferator, and FORIS AG—that combine intriguing prospects with the inherent risks of small-cap investing.

Jan 30, 2026

Business

Hycroft Mining Shares Tumble Over 11% as Precious Metals Retreat from Peaks

Hycroft Mining Holding Corp. (HYMC) fell sharply for a second consecutive session, mirroring a pullback in gold and silver prices after their record-breaking rallies. The decline highlights the stock's sensitivity to commodity price swings despite recent positive operational updates.

Jan 30, 2026

Business

Asian Markets Retreat as Wall Street's Wild Ride Casts a Shadow

Asian equities broadly declined on Friday, taking cues from a volatile U.S. session marked by a historic plunge in Microsoft shares. The sell-off extended to commodities, with oil and precious metals also losing ground.

Jan 30, 2026

Business

C3.ai Remains a Lightning Rod in AI Investment Debate Amid Capital Concerns

While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.

Feb 2, 2026

Business

Intellia Therapeutics Sees Analyst Price Target Surge After FDA Lifts Clinical Hold on Key Gene Therapy Trial

Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.

Feb 2, 2026

Business

Janux Therapeutics Downgraded as Key Drug Data Gaps Raise Platform Concerns

Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.

Feb 2, 2026

Business

Kura Oncology Eyes 2026 as Pivotal Year Amid Pipeline Expansion and Analyst Scrutiny

Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.

Feb 2, 2026

Business

Goldman Sachs Downgrades MoonLake to Sell, Citing Trial Setback and Regulatory Hurdles

Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.

Feb 2, 2026

Business

ExxonMobil Posts Record 2025 Results, Cementing Its Dominance in the Oil Sector

The energy giant reported industry-leading earnings and cash flow, driven by record production and deep cost cuts, while returning billions to shareholders and outlining an ambitious growth plan through 2030.

Feb 2, 2026